Kymera Therapeutics Inc Forecast, price target & analysts
Kymera Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Kymera Therapeutics Inc Classifications & Recommendation
Kymera Therapeutics Inc Price Target
| Target Price | $136.68 |
| Price | $117.75 |
| Potential |
16.08%
register free of charge
|
| Number of Estimates | 24 |
|
24 Analysts have issued a price target Kymera Therapeutics Inc 2027 .
The average Kymera Therapeutics Inc target price is $136.68.
This is
16.08%
register free of charge
$162.75
38.22%
register free of charge
$112.11
4.79%
register free of charge
|
|
| A rating was issued by 30 analysts: 26 Analysts recommend Kymera Therapeutics Inc to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Kymera Therapeutics Inc stock has an average upside potential 2027 of
16.08%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 39.21 | 107.39 |
| 16.70% | 173.88% | |
| EBITDA Margin | -860.06% | -396.67% |
| 62.36% | 53.88% | |
| Net Margin | -794.06% | -300.51% |
| 66.96% | 62.16% |
25 Analysts have issued a sales forecast Kymera Therapeutics Inc 2026 . The average Kymera Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Kymera Therapeutics Inc EBITDA forecast 2026. The average Kymera Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 Kymera Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Kymera Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.69 | -3.90 |
| 23.83% | 5.69% | |
| P/E | negative | |
| EV/Sales | 84.76 |
25 Analysts have issued a Kymera Therapeutics Inc forecast for earnings per share. The average Kymera Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Kymera Therapeutics Inc...
Current Kymera Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B of A Securities |
Locked
➜
Locked
|
Locked | Sep 14 2026 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Sep 10 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 31 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 27 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Deutsche Bank |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jul 28 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
B of A Securities:
Locked
➜
Locked
|
Sep 14 2026 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Sep 10 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 31 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 27 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
Deutsche Bank:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jul 28 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
